Q&A

Exclusive interviews with industry leaders


  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners

    With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth. 

    Amy Baxter • June 24, 2024
  • Medicine capsules on blue racing lines
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In an era of big patent losses, drug launches need years of runway

    Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.

    Amy Baxter • June 3, 2024
  • Enhertu
    Image attribution tooltip
    Permission granted by Daiichi Sankyo
    Image attribution tooltip

    The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel

    The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.

    Meagan Parrish • May 10, 2024
  • Mohit Manrao, head of U.S. oncology, AstraZeneca
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip

    AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist

    Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.

    Michael Gibney • May 8, 2024
  • An illustration of transfer RNA from Alltrna.
    Image attribution tooltip
    Courtesy of Alltrna
    Image attribution tooltip

    How a biotech exec is leveraging Big Pharma lessons to advance tRNA

    Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.

    Amy Baxter • April 29, 2024
  • Jeremy Levin
    Image attribution tooltip
    Permission granted by Ovid Therapeutics
    Image attribution tooltip

    Neuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.

    Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.

    Meagan Parrish • April 26, 2024
  • Halftone collage of eye on dark background.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy

    After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy.

    Amy Baxter • April 24, 2024
  • Raj Indupuri, CEO, eClinical Solutions
    Image attribution tooltip
    Permission granted by eClinical Solutions
    Image attribution tooltip

    How pharma’s surging M&A is impacting the industry’s tech sector

    As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.

    Michael Gibney • April 11, 2024
  • Daniel Paterson, CEO, Verastem Oncology
    Image attribution tooltip
    Permission granted by Verastem
    Image attribution tooltip

    With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

    As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.

    Michael Gibney • April 4, 2024
  • Lori Lebson, EMD Serono
    Image attribution tooltip
    Permission granted by EMD Serono
    Image attribution tooltip

    To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec

    Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.

    Alexandra Pecci • April 1, 2024
  • A headshot of Armon Sharei, CEO of Portal Bio.
    Image attribution tooltip
    Permission granted by Portal Bio
    Image attribution tooltip

    SQZ, Portal founder Armon Sharei on starting over in biotech

    After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.

    Gwendolyn Wu • March 26, 2024
  • Boehringer Ingelheim building
    Image attribution tooltip
    Permission granted by Boehringer Ingelheim
    Image attribution tooltip

    Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim

    Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”

    Alexandra Pecci • March 25, 2024
  • Bogdan Budnik, principal scientist, Wyss Institute at Harvard University
    Image attribution tooltip
    Permission granted by Wyss Institute
    Image attribution tooltip

    An ocean of answers in a single cell — how proteomics can lead to better drugs

    New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.

    Michael Gibney • March 21, 2024
  • shingles vaccine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

    Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

    Alexandra Pecci • March 19, 2024
  • U.S. President Joe Biden
    Image attribution tooltip
    Alex Wong/Getty Images via Getty Images
    Image attribution tooltip

    Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

    A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

    Michael Gibney • March 14, 2024
  • Bobak Azamian horizontal no logo
    Image attribution tooltip
    Permission granted by Tarsus Pharmaceuticals
    Image attribution tooltip

    Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category

    The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.

    Meagan Parrish • March 8, 2024
  • Neuron ALS
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Biogen partner NeuroSense seeks a role in the ALS revolution

    Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

    Michael Gibney • Feb. 29, 2024
  • Moderna company name on side of building
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

    Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

    Amy Baxter • Feb. 23, 2024
  • Caroline Loew, chief executive officer of Mural Oncology
    Image attribution tooltip
    Permission granted by Mural Oncology
    Image attribution tooltip

    Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

    With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

    Alexandra Pecci • Feb. 6, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    Meagan Parrish • Jan. 26, 2024
  • 4D Molecular Therapeutics CEO David Kirn
    Image attribution tooltip
    Permission granted by 4DMT
    Image attribution tooltip

    One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery

    4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.

    Michael Gibney • Jan. 10, 2024
  • Gene editing
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

    Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

    Michael Gibney • Dec. 19, 2023
  • Quita Highsmith header
    Image attribution tooltip
    Permission granted by Quita Highsmith
    Image attribution tooltip

    The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

    Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.

    Michael Gibney • Dec. 14, 2023
  • Dr. Julie Gerberding headshot
    Image attribution tooltip
    Permission granted by FNIH
    Image attribution tooltip

    A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

    Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

    Meagan Parrish • Dec. 13, 2023
  • Professional photo of Adam Lenkowsky
    Image attribution tooltip
    Permission granted by Adam Lenkowsky
    Image attribution tooltip

    Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

    Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

    Michael Gibney • Dec. 12, 2023